Use of Parenteral Prostanoids at Time of Death in Patients With Pulmonary Arterial Hypertension Enrolled in REVEAL

Abstract

PURPOSE: A primary objective of the Registry to EValuate Early And Long-term Pulmonary Arterial Hypertension (PAH) Disease Management (REVEAL) is to determine outcomes in patients with PAH. Analysis of PAH-specific therapy at time of death could provide information on the aggressiveness of therapy and the adherence to recommended treatment guidelines in patients with the most severe disease. In this study, we compared functional class assessments prior to death and parenteral prostanoid administration at time of death to determine whether PAH patients were treated according to recommendations.